Synergistic anti-tumor activity of the mTOR inhibitor everolimus and gemcitabine for relapsed/refractory peripheral T cell lymphoma.

ABSTRACT:

Background

Relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) patients face poor prognosis and limited therapies. The mTOR inhibitor everolimus and gemcitabine show modest efficacy as single agents in R/R PTCL, warranting investigation of combination regimens.

Methods

This study conducted a single-center retrospective analysis of 24 patients diagnosed with peripheral T-cell lymphoma, aged 18 to 70 years, who experienced relapse or refractory disease following at least one first-line chemotherapy regimen, and received treatment at Guangdong Provincial People's Hospital between December 2017 and March 2021. CellTiter Glo and AnnexinV FITC/PI assays evaluated cell viability and apoptosis in vitro.

Results

The combination showed significant efficacy: objec

SUBMITTER: Huang L 

PROVIDER: S-EPMC12698551 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature